Rhythm Pharmaceuticals is awaiting a decision from the Food and Drug Administration (FDA) regarding its drug IMCIVREE for acquired hypothalamic obesity, a condition resulting from damage to the hypothalamus. The FDA extended its review of the application in February, according to a statement from Rhythm Pharmaceuticals reported by GlobeNewswire.
The company is simultaneously preparing for a potential U.S. Commercial launch of IMCIVREE for this indication, although likewise advancing a Phase 3 clinical trial program for its oral candidate, bivamelagon. Rhythm reported constructive feedback from the FDA following an end-of-Phase 2 meeting regarding bivamelagon, bolstering plans to move forward with the next stage of development.
Rhythm’s broader strategy includes expanding commercial access, securing reimbursement, and extending its geographic reach into Europe and Japan for its portfolio of treatments targeting rare neuroendocrine diseases. The company’s stock (NasdaqGM:RYTM) has experienced significant volatility, trading around $92.73 as of today, March 2, 2026. While the stock has seen a substantial gain over the past three years and a 68.9% return over the last year, it has declined by 11.7% year-to-date.
Analysts at Simply Wall St. Note that Rhythm Pharmaceuticals currently trades approximately 34% below the midpoint of analyst price targets, which stand at $140.67. The firm also estimates the company’s shares are trading at roughly 78.5% below their estimated fair value. However, the stock has experienced a 9.5% decline in the last 30 days.
Rhythm Pharmaceuticals reported a net loss of $201.9 million and currently has a price-to-earnings ratio of approximately 31, reflecting the financial investment required to support its clinical and commercial programs. The company’s revenue currently stands at $189.8 million. Investors are focused on the timing and outcome of the FDA’s decision on IMCIVREE, as well as the potential for label expansions and revenue growth as new indications and regions are addressed.
The company is concentrating on rare neuroendocrine conditions where treatment options are limited. The FDA’s decision on IMCIVREE will be a key catalyst for the company, alongside the progress of the bivamelagon Phase 3 program and the expansion efforts in Europe and Japan.
